You are here: Industry Insights > CureVac

News List

EU, CureVac may sign deal for 225 million doses of COVID-19 vaccine expresspharma
August 21, 2020
CureVac said it could start large-scale human trials on its vaccine in the last quarter of this year based on results of its current trials.
CureVac Appoints CEO and COO contractpharma
August 06, 2020
Names Dr. Franz-Werner Haas and Igor Splawski, Ph.D. to executive positions.
GSK Buys 10% Stake in German Vaccine Developer CureVac contractpharma
July 22, 2020
Companies will collaborate on the research and development mRNA vaccine candidates.
GSK to obtain 10% stake in vaccines maker CureVac for $163m pharmaceutical-technology
July 21, 2020
GlaxoSmithKline (GSK) has signed an agreement with German company CureVac to research, develop, manufacture and commercialise up to five mRNA-based vaccines and monoclonal antibodies (mAbs) against infectious diseases.
CureVac recieves €75 million loan for vaccine development and manufacturing expansion europeanpharmaceuticalreview
July 09, 2020
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
CureVac nets EU funding to ramp up vaccine production expresspharma
July 07, 2020
CureVac, backed by the Bill & Melinda Gates Foundation, is a pioneer in the so-called messenger RNA approach, which is also being pursued by BioNTech and its partner Pfizer as well as Moderna.
CureVac Receives Approval to Initiate Clinical Trial of SARS-CoV-2 Vaccine Candidate contractpharma
June 18, 2020
The Belgian Federal Agency for Medicines and Health Products (FAMHP) has approved the Phase 1 clinical trial for CureVac’s vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.
Germany to invest €300m in CureVac’s mRNA platform technology pharmaceutical-technology
June 17, 2020
The German Federal Government is set to invest €300m in CureVac, a biotechnology company focused on using messenger RNA (mRNA) technology to develop drugs and vaccines.
German Government, dievini Invests €300M in CureVac contractpharma
June 16, 2020
To expand business activities and further develop CureVac’s pipeline and mRNA platform technology.
EC offers €80m to CureVac for COVID-19 vaccine development europeanpharmaceuticalreview
March 20, 2020
The European Commision (EC) has announced €80 million of support to aid in the R&D and production of a COVID-19 coronavirus vaccine.

Previous page 1 2 3 4 5 Next page